Significant Ownership of Chee Kong Choo

Large-stake snapshot 1 signal
Large-stake filing summary
  • Recent SEC Schedule 13D/G filings for Chee Kong Choo focus on large-stake beneficial ownership disclosures and amendments.
  • Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager signature
/s/ Choo Chee Kong - Choo Chee Kong / Chairman and Director of CytoMed Therapeutics Limited
Manager location
Singapore, Singapore

Follow Filing Activity

Follow Chee Kong Choo with Pro and return when a new Schedule 13D/G filing changes the record on this page.

Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.

Review Pro alert access Already have an account? Sign in and return here

Significant Ownership of Chee Kong Choo

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GDTC CytoMed Therapeutics Limited Ordinary Shares 22% $5,046,105 -$166,879 2,587,746 -3.2% Choo Chee Kong 29 Oct 2025

Schedules 13D/G Reported by Chee Kong Choo:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .